Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and meta-analysis

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Evidence for implantable cardioverter defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) for primary prevention of sudden cardiac death (SCD) is limited.
• Assessing the impact of routine ICD implantation is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the effect of routine ICD implantation on mortality due to SCD in NICM patients.
• To analyze data from all published randomized clinical trials (RCTs) on this topic.

Main Methods:

• A meta-analysis of six RCTs identified through PubMed/Medline, EMBASE, and CENTRAL databases.
• Outcomes were analyzed using random-effects relative risk (RR) and risk difference (RD) with 95% confidence intervals (CI).
• Patients were randomized to ICD or control (usual care/medical treatment).

Main Results:

• ICDs significantly reduced all-cause mortality in NICM patients (RR, 0.74; 95% CI, 0.56-0.97).
• This mortality benefit was driven by a significant reduction in SCD (RR, 0.47; 95% CI, 0.30-0.73).
• No significant differences were observed in noncardiac mortality, non-SCD, cardiac arrest, cardiac transplant, or ventricular tachycardia (VT) events.

Conclusions:

• Routine ICD implantation is effective in reducing all-cause mortality in NICM patients.
• The primary mechanism for mortality reduction is a significant decrease in sudden cardiac death.
• ICDs are a valuable tool for primary prevention of SCD in select NICM populations.